Stephens & Co. Reiterates Overweight on Candel Therapeutics, Maintains $15 Price Target

Benzinga · 1d ago
Stephens & Co. analyst Sudan Loganathan reiterates Candel Therapeutics (NASDAQ:CADL) with a Overweight and maintains $15 price target.